Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NF-κB activation

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 480-481, Issue , 2001, Pages 243-268

  Surh, Young Joon ^a   Chun, Kyung Soo ^a   Cha, Hyun Ho ^a   Han, Seong Su ^a   Keum, Young Sam ^a   Park, Kwang Kyun ^b   Lee, Sang Sup ^a  

^a Seoul National University   (South Korea)

^b Yonsei University College of Dentistry   (South Korea)

Author keywords

Chemopreventive phytochemicals; Curcumin; Cyclooxygenase; Epigallocatechin gallate; Inducible nitric oxide synthase; NF B; Resveratrol

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NITRIC OXIDE SYNTHASE; PIROXICAM; PLANT EXTRACT; PROTEIN KINASE; PROTEIN SUBUNIT; RESVERATROL; SULINDAC; THIOUREA DERIVATIVE;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL ADHESION; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INDUCTION; ENZYME REGULATION; GENE TRANSLOCATION; GENOTOXICITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STIMULUS RESPONSE; TUMOR CELL; TUMOR PROMOTION;

CURCUMA LONGA; EUKARYOTA; VITACEAE; VITIS VINIFERA; ZINGIBERACEAE;

EID: 0035451363     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(01)00183-X     Document Type: Article

References (304)

1. Regulation of immune response by prostaglandins
2. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo
3. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
4. Prostaglandins and breast cancer
5. Prostaglandins from tumors of human large bowel
6. Prostaglandin-like material extracted from squamous carcinomas of the head and neck
7. The production of prostanoids in human cancers, and their implications for tumor progression
8. Prostaglandins and human lung carcinomas
9. Altered eicosanoid levels in human colon cancer
10. Arachidonic acid metabolites in cutaneous carcinoma
11. Differential expression of prostaglandin H synthase isozymes during multi-stage carcinogenesis in mouse epidermis
12. Inhibition of lung tumorigenesis by sulindac: Comparison of two experimental protocols
13. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention
14. Aspirin and the potential role of prostaglandins on colon cancer
15. Modulation of rat mammary carcinogenesis by indomethacin
16. Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin
17. Chemoprevention of colon carcinogenesis by sulindac: A nonsteroidal anti-inflammatory agent
18. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
19. Cyclooxygenase overexpression and tumor formation are blocked by sulindac in murine model of familial polyposis
20. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine
21. Aspirin and the risk of colorectal cancer in women
22. Reduced risk of large-bowel adenomas among aspirin users
23. Aspirin use and lung, colon and breast cancer incidence in a prospective study
24. Aspirin, NSAIDs and digestive tract cancers
25. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
26. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
27. Sulindac for polyposis of the colon
28. The NSAID sulindac reverses rectal adnomatous polyposis: Clinical trials of a dose-finding study on rectal sulindac administration
29. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues
30. Cyclooxygenases 1 and 2
31. Prostaglandin endoperoxide synthase: Why two isoforms?
32. Cyclooxygenase-2 induction: Molecular mechanism and pathophysiologic roles
33. Arachidonic acid oxygenation by Cox-1 and Cox-2
34. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of head and neck
35. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
36. Persistent induction of cyclooxygenase on p60 v-src-transformed 3T3 fibroblasts
37. Localization of prostaglandin H synthase isozymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2
38. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas
39. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
40. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
41. Expression of cyclooxygenase-2 in human gastric carcinoma
42. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
43. A selective cyclooxygenase-2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells
44. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells
45. Cycoloxygenase-2 expression is up-regulated in human pancreatic cancer
46. Expression of cyclooxygenase-2 in human lung carcinoma
47. v-src induces prostaglandin synthase-2 gene expression by activation of the c-Jun N-terminal kinase and c-Jun transcription factor
48. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
49. Cyclooxygenase-2 expression in human esophageal carcinoma
50. The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells
51. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis
52. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
53. Apoptosis primarily accounts for the growth inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
54. Malignant transformation and anti-neoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts
55. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
56. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2
57. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
58. Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinase (TIMP-1) and pro-matrix metalloproteinase-1 (proMMP-1) in human rheumatoid synovial fibroblasts
59. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase-2 (COX-2)
60. COX-2 and colon cancer
61. Inhibition of cyclooxygenase: A novel approach to cancer prevention
62. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis
63. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
64. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor
65. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
66. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
67. Chronic infections and inflammatory processes as cancer risk factors: Possible role of nitric oxide in carcinogenesis
68. The multifaceted roles of nitric oxide in cancer
69. Nitric oxide and oxygen radicals in infection, inflammation, and cancer
70. Mutagenesis associated with nitric oxide production in macrophages
71. DNA damage and mutation in human cells exposed to nitric oxide in vitro
72. Gene expression and cellular sources of inducible nitric oxide synthase during tumor promotion
73. Inhibitors of endogenous nitrogen oxide formation block the promotion of neoplastic transformation in C3H 10T1/2 fibroblasts
74. Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells
75. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vivo promoted by substance P
76. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium
77. Roles of nitric oxide in tumor growth
78. Reaction of superoxide with nitric oxide to form peroxynitrite in alkaline aqueous solution
79. The reaction of nitric oxide with superoxide
80. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial cell injury from nitric oxide and superoxide
81. Superoxide modulates the oxidation and nitrosation of thiols by nitric oxide derived reactive intermediates
82. On the pH-dependent yield of hydroxyl radical products from peroxynitrite
83. Nitric oxide induces oxidative damage in addition to deamination in macrophage DNA
84. Formation of 8-nitroguanine by the reaction of guanine with peroxynitrite in vitro
85. Formation of 8-nitroguanine in DNA treated with peroxynitrite in vitro and its rapid removal from DNA by depurination
86. Peroxynitrite causes DNA nicks in plasmid pBR322
87. A stable solid that generates hydroxyl radical upon dissolution in aqueous solution: Reactions with proteins and nucleic acids
88. DNA damage induced by peroxynitrite: Subsequent biological effects
89. Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide
90. Nitric oxide activation of poly(ADP-ribose)synthetase in neurotoxicity
91. p53 expression in nitric oxide-induced apoptosis
92. Nitric oxide-induced p53 accumulation and regulation of inducible-nitric oxide synthase expression in wild-type p53
93. Mechanisms of cell death induced by nitric oxide and peroxynitrite in Calu-1 cells
94. Molecular mechanisms of apoptosis in HL-60 cells induced by a nitric oxide-releasing compound
95. Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine
96. Nitric oxide-mediated apoptosis in murine peritoneal macrophages
97. Reactive oxygen species participate in peroxynitrite-induced apoptosis in HL-60 cells
98. Role of nitric oxide and peroxynitrite in bile salt-induced apoptosis: Relevance to colon carcinogenesis
99. Studies of iron deposits, inducible nitric oxide synthase and nitrotyrosine in a rat model for esophageal adenocarcinoma
100. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinoma
101. Nitric oxide synthase activity in human gynecological cancer
102. Nitric oxide synthase activity in human breast cancer
103. Human colorectal adenocarcinoma cells: Differential nitric oxide synthesis determines their ability to aggregate platelets
104. Increased expression of inducible and endothelial nitric oxide synthases in rat colon tumors induced by azoxymethane
105. Frequent nitric oxide synthase-2 expression in human colon adenomas: Implication for tumor angiogenesis and colon cancer progression
106. Role of iNOS in gut inflammation and injury
107. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages
108. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor
109. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis
110. New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases
111. Oxidation/reduction status in the regulation of transcription factors NF-κB and AP-1
112. Transcription factor NF-κB: An emerging anti-inflammatory drug target
113. Rel/NF-κB and IκB factors in oncogenesis
114. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer
115. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
116. Increased expression of p50-NF-κB and constitutive activation of NF-κB transcription factors during mouse skin carcinogenesis
117. Activation of NF-κB/Rel occurs early during neoplastic transformation of mammary cells
118. NF-κB is required for H-ras oncogene-induced abnormal cell proliferation and tumorigenesis
119. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
120. Constitutive activation of NF-κB causes resistance to apoptosis in human cutaneous T-cell lymphoma HuT-78 cells
121. Life-death balance within the cell
122. Rel/NF-κB transcription factors and the control of apoptosis
123. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
124. An essential role for NF-κB in preventing TNF-α-induced cell death
125. Suppression of TNF-α-induced apoptosis by NF-κB
126. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevent cell death
127. Involvement of NF-κB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages
128. Lipopolysaccharide increases cyclooxygenase-2 expression in a colon carcinoma cell line through nuclear factor-κB activation
129. Transcriptional roles of nuclear factor-κB and nuclear factor-interleukin-6 in the tumor necrosis factor-α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells
130. Evidence for involvement of NF-κB in the transcriptional control of COX-2 gene expression by IL-1β
131. Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells
132. Specific NF-κB blockade selectively inhibits tumor necrosis factor-α-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells
133. Inhibition of NF-κB binding by sodium salicylate and aspirin
134. Aspirin inhibits tumor necrosis factor-α gene expression in murine tissue macrophages
135. Sodium salicylate inhibits cyclooxygenase-2 activity independently of transcription factor (nuclear factor-κB) activation: Role of arachidonic acid
136. Inhibition of cyclooxygenase-2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signaling complex
137. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase
138. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages
139. Oxidative stress induces NF-κB DNA binding and inducible NOS mRNA in human epithelial cells
140. Hepatic ischemia/reperfusion in rats induces iNOS gene expression by activation of NF-κB
141. NF-kappaB-dependent expression of nitric oxide synthase is required for membrane fusion of chick embryonic myoblasts
142. Inhibition of activation of nuclear factor-κB is responsible for inhibition of inducible nitric oxide synthase expression by higenamine, an active component of aconite root
143. Evidence that inducible nitric oxide synthase in rat skin is involved in LPS-induced plasma leakage in rat skin through the activation of nuclear factor-κB
144. Altered expression of β-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis
145. Antioxidants inhibit interleukin-1-induced cyclooxygenase and nitric oxide synthase expression in rat mesangial cells
146. Co-regulation between cyclooxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation
147. Dual inhibition of nitric oxide and prostaglandin production contributes to the anti-inflammatory properties of nitric oxide synthase inhibitors
148. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation
149. Co-induction of nitric oxide synthase and cyclooxygenase: Interactions between nitric oxide and prostanoids
150. Cyclooxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy
151. Inhibition of NF-κB, iNOS mRNA, COX-2 mRNA, and COX catalytic activity by phenyl-N-tert-butylnitrone
152. New concepts in inflammation and therapy
153. Role of nitric oxide in the regulation of cyclooxygenase
154. Modulation by nitric oxide of prostaglandin biosynthesis in the rat
155. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors
156. Nitric oxide activates cyclooxygenase enzymes
157. Mechanisms of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide
158. Nitric oxide as an antioxidant
159. Dual effect of nitric oxide donors on cyclooxygenase-2 expression in human mesangial cells
160. 2 synthesis is differentially affected by reactive nitrogen intermediates in cultured rat microglia and RAW 264.7 cells
161. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages
162. Articular chondrocytes synthesize nitric oxide to cytokines and lipopolysaccharide
163. 2 production by vascular smooth muscle cells
164. Cyclooxygenase-2: An essential regulator of NO-mediated apoptosis
165. IL-1β induces the co-expression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: Activation of cyclooxygenase by nitric oxide
166. Regulation of prostacyclin synthesis by the release of endogenous nitric oxide in response to bacterial lipopolysaccharide
167. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells
168. Modulation of the induction of nitric oxide synthase by eicosanoids in the murine macrophage cell line J774
169. 2 regulates inducible nitric oxide synthase in the murine macrophage cell line J774
170. The mitogen-activated protein kinase signal transduction pathway
171. Mitogen-activated protein kinase cascades and regulation of gene expression
172. From receptors to stress-activated MAP kinases
173. p38 MAPK signalling cascades in inflammatory disease
174. Human mitogen-activated protein kinase kinase kinase mediates the stress-induced activation of mitogen-activated protein kinase cascades
175. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide
176. Induction of cyclooxygenase-2 expression by methyl arachidonyl fluorophosphonate in murine J774 macrophages: Roles of protein kinase C, ERKs and p38 MAPK
177. MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocytes
178. 2 production in lipopolysaccharide-stimulated monocytes
179. Inhibition of MAP kinase kinase (MEK) results in an anti-inflammatory response in vivo
180. 2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells
181. v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor
182. Induction of cyclooxygenase-2 by activated H-ras oncogene in rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway
183. Oncogenic Ha-ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation
184. 2 by oncogenic ras in human non-small cell lung cancer
185. Ras-independent activation of Rel-family transcription factors by UVB and TPA in cultured keratinocytes
186. Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway
187. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation
188. Differential regulation of IκB kinase α and β by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1
189. Vanadate induction of NF-κB involves IκB kinase β and SAPK/ERK kinase 1 in macrophages
190. Mitogen-activated protein kinase/ERK kinase kinase 2 and 3 activate nuclear factor-κB through IκB kinase α and IκB kinase β
191. Superinduction of COX-2 mRNA by cycloheximide and interleukin-1β involves increased transcription and correlates with increased NF-κB and JNK activation
192. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2
193. MEK kinase is involved in tumor necrosis factor alpha-induced NF-kappaB activation and degradation of IκBβ
194. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1
195. The p38 mitogen-activated kinase is required for NF-κB-dependent gene expression
196. Cell stress and MKK6β-mediated p38 MAP kinase activation inhibit tumor necrosis factor-induced IκB phosphorylation and NF-κB activation
197. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
198. Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium
199. From receptors to stress-activated MAP kinases
200. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis
201. 2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in palitaxel-mediated apoptosis in human B-lymphocytes
202. c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide
203. The cellular response to oxidative stress: Influences of mitogen-activated protein kinase signalling pathways on cell survival
204. The regulation of AP-1 activity by mitogen-activated protein kinases
205. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways
206. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response
207. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage-independent growth of HPV immortalized human keratinocytes
208. JNK or IKK, AP-1 or NF-κB, which are the targets for MEK kinase 1 action?
209. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-κB
210. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2
211. Temporal effects of the detoxification enzyme inducer, benzyl isothiocyanate: Activation of c-Jun N-terminal kinase prior to the transcription factors AP-1 and NF-κB
212. Increased ROS levels contribute to elevated transcription factor and MAP kinase activities in malignantly progressed mouse keratinocyte cell line
213. Pharmacology of Curcuma longa
214. Pharmacology of diferuloylmethane (curcumin), a non-steroidal anti-inflammatory agent
215. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances
216. Inhibition of chemical carcinogenesis by curcumin
217. Curcumin, an inhibitor of cancer
218. Some perspectives on dietary inhibition of carcinogenesis: Studies with curcumin and tea
219. Inhibitory effects of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced increase in ornithine decarboxylase mRNA in mouse epidermis
220. Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis
221. Inhibitory effects of curcumin and tetrahydrocurcuminoids on the tumor promoter-induced reactive oxygen species generation in leukocytes in vitro and in vivo
222. Inhibitory effect of curcumin on xanthine dehydrogenase/oxidase induced by phorbol-12-myristate-13-acetate in NIH3T3 cells
223. Anti-tumor promoting potential of naturally occurring diarylheptanoids structurally related to curcumin
224. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis
225. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets
226. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells
227. Curcumin, an anti-tumor promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages
228. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties
229. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells
230. A labile hyperphosphorylated c-Fos protein is induced in mouse fibroblast cells treated with a combination of phorbol ester and anti-tumor promoter curcumin
231. Curcumin inhibits TPA-induced expression of c-fos, c-jun, c-myc proto-oncogenes messenger RNAs in mouse skin
232. Effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate- and ultraviolet B light-induced expression of c-Jun and c-Fos in JB6 cells and in mouse epidermis
233. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-κB
234. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin
235. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane)
236. Curcumin blocks cytokine-mediated NF-κB activation and pro-inflammatory gene expression by inhibiting inhibitory factor IκB kinase activity
237. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoylphorbol-13-acetate in NIH3T3 cells
238. L-929 cells harboring ectopically expressed RelA resist curcumin-induced apoptosis
239. Curcumin induces apoptosis in immortalized NIH3T3 and malignant cancer cell lines
240. Anti-proliferative effects of curcumin (diferuloylmethane) against human breast tumor cell lines
241. Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway
242. Differential regulation of p53, c-Myc, Bcl-2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells
243. Curcumin-mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen species
244. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by down-regulation of egr-1, c-myc, bcl-XL, NF-κB, and p73
245. Inhibition of proliferation and apoptosis of human and rat T-lymphocytes by curcumin, a curry pigment
246. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells
247. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin
248. Anti-apoptotic effect of quercetin: Intervention in the JNK- and ERK-mediated apoptotic pathways
249. Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells
250. Green tea and cancer chemoprevention
251. Antimutagenic and anticarcinogenic activity of tea polyphenols
252. Mechanism of cancer chemopreventive activity of green tea
253. Polyphenols as cancer chemopreventive agents
254. Inhibition of carcinogenesis by tea
255. A new tumor promotion pathway and its inhibitors
256. Effects of epigallocatechin gallate and quercetin on oxidative damage to cellular DNA
257. (-)-Epigallocatechin gallate, a polyphenolic tea antioxidant, inhibits peroxynitrite-mediated formation of 8-oxodeoxyguanosine and 3-nitrotyrosine
258. Inhibition of peroxynitrite-mediated tyrosine nitration by catechin polyphenols
259. Antioxidant and pro-oxidant actions of flavonoids: Effects on DNA damage induced by nitric oxide, peroxynitrite and nitroxyl anion
260. Diffusion of peroxynitrite into the human platelet inhibits cyclooxygenase via nitration of tyrosine residues
261. Effects of three dietary phytochemicals from tea, rosemary and turmeric on inflammation-induced nitrite production
262. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-κB
263. Inhibition of inducible nitric oxide synthase gene expression and enzyme activity by epigallocatechin gallate, a natural product from green tea
264. Promoter of the mouse gene encoding calcium-dependent nitric oxide synthase confers inducibility by interferon-γ and bacterial lipopolysaccharide
265. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells
266. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts
267. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols
268. Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate
269. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor-κB in cancer cells versus normal cells
270. Mechanistic aspects of green tea as a cancer preventive: Effect of components on human stomach cancer cell lines
271. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model
272. Antioxidant properties of (-)-epigallocatechin-3-gallate and its inhibition of Cr(VI)-induced DNA damage and Cr(IV)- or TPA-stimulated NF-κB activation
273. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced NF-κB activation by tea polyphenols: (-)-epigallocatechin gallate and theaflavins
274. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade
275. Signal transduction events elicited by natural products: Role of MAPK and caspase pathways in homeostatic response and induction of apoptosis
276. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin-3-gallate in human A431 epidermoid carcinoma cells
277. Inhibitory effects of phytopolyphenols on TPA-induced transformation, PKC activation, and c-jun expression in mouse fibroblast cells
278. Inhibition of oncogene expression by green tea and (-)-epigallocatechin gallate in mice
279. (-)-Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity
280. Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins
281. Inhibition of ultraviolet B-induced AP-1 activation by theaflavins from black tea
282. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: Structure-activity relationship and mechanisms involved
283. Inhibition of ultraviolet B-induced c-fos gene expression and p38 mitogen-activated protein kinase activation by (-)-epigallocatechin gallate in a human keratinocyte cell line
284. Epigallocatechin-3-gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of cis-transfected NIH3T3 fibroblasts and human glioblastoma cells (A172)
285. Activation of mitogen-activated protein kinase by green tea polyphenols: Potential signaling pathways in the regulation of antioxidant-responsive element-mediated Phase-II enzyme gene expression
286. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
287. Modulation by phytochemicals of cytochrome P450-linked enzyme activity
288. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor
289. Inhibition of arylhydrocarbon-induced cytochrome P4501A1 enzyme activity and CYP1A1 expression by resveratrol
290. Resveratrol is a selective human cytochrome P4501A1 inhibitor
291. Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin
292. Inhibitory effects of resveratrol analogs on unopsonized zymogen-induced oxygen radical production
293. Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes
294. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production
295. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells
296. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure
297. Suppression of nitric oxide synthase and the down-regulation of the activation of NF-κB in macrophages by resveratrol
298. Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages
299. Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric oxide synthase pathway
300. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase
301. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation
302. Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: Reversal of endothelin-1 stimulatory effects
303. Resveratrol-induced activation of the mitogen-activated protein kinases, ERK1 and ERK2, in human neuroblastoma SH-SY5Y cells
304. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells